Genome Editing/ Genome Engineering Market By Technology Type (CRIPR/CAS 9, TALENs/ MEGATALs, ZFN, Mega nucleases, & Others), By Delivery Method (Ex-Vivo & In-Vivo), By Application (Genetic Engineering & Clinical Applications), By End Use (Biotechnology & Pharmaceutical Companies, Academia & Research Centers, Contract Research Organizations, & Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027
Genome Editing/Genome Engineering Market Overview
The Genome Editing/ Genome Engineering Market size is estimated to reach $2.4 million by 2027. Furthermore, it is poised to grow at a CAGR of 12.9% over the forecast period of 2022-2027. Genome editing refers to the practice by which scientists can alter the DNA of various organisms, including plants, animals, bacteria, and others. Genome engineering allows scientists to change or cut the DNA at the desired spot and they engraft the entire structure of others. The changes pertaining to genome editing can lead to change in eye color or various other physical structures. The technology to edit or genetic engineering was developed in the late 1900s, only after much research back in 2009, CRISPR technologies allowed the scientist to edit DNA. Moreover, the technology was faster, simpler, cheaper, and more accurate than previous articulations. Stem cell therapies have been actively making use of genome editing as with the latter’s introduction, human genetics and regenerative medicines can be highly evolved. Owing to the growth in diseases across the globe and the preference for choosing regenerative medicines along with the use of AI and IoT in gene modification tools for therapeutic research are some of the key factors driving the genome editing/genome engineering industry forward in the projected period of 2022-2027.
The report: “Genome Editing/Genome Engineering Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Genome Editing/Genome Engineering Market.
By Technology Type- CRIPR/CAS 9, TALENs/ MEGATALs, ZFN, Mega
nucleases, and Others.
By Delivery Method- Ex-Vivo and In-Vivo.
By Application – Genetic Engineering and Clinical Applications.
By End Use- Biotechnology and Pharmaceutical Companies, Academia and Research Centers, Contract Research Organizations, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).
- Geographically, North America’s Genome Editing/Genome Engineering Market held a dominant market share in 2021. It is owing to its use in various end varieties of crops to modify the crops to yield better results. Additionally, the region’s predominant position in local infrastructure pertaining to giant bio-pharma companies. However, Asia-Pacific is set to offer lucrative growth opportunities. It is owing to the region’s new policies, which allow the foreign developers to outsource the services to regions such as India and China. Moreover, they can increase heightened efficiency and low labor costs, amongst many advantages.
- The advent of AI and IoT within genomic editing or engineering has allowed the market to grow multifold and has acted as a key diver for growth. However, high costs pertaining to the research and low-skilled professionals are the key challenges faced by the market.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Genome Editing/Genome Engineering Market Report.
Genome Editing/Genome Engineering Market- Geography (%) for 2021.
For More Details on This Report - Request for Sample
Genome Editing/Genome Engineering Market Segmentation Analysis- By Application
The genome editing/ genome engineering market based on the application can be further segmented into genetic engineering and clinical applications. Genetic engineering held a dominant market share in the year 2021. It is owing to the rising adoption of gene and stem cell therapy and the need to find better and better products. Moreover, genetic engineering helps in the mass production of insulin, human growth hormones, Follistim, monoclonal antibodies, and various other drugs. Monoclonal antibodies were being prevalently used in the treatment of severe COVID-19. Additionally, monoclonal antibodies allowed the body to not attach its cells to latch on the virus, and thereby allowing to neutralize the virus. As of 31st October, 250 million people have had COVID-19. Additionally, people suffering from diabetes and other cardiovascular diseases were attributed to developing severe COVID-19, and hence monoclonal antibodies were readily given to such patients.
Moreover, genetic engineering is estimated to be the fastest-growing, with a CAGR of 13.6% over the forecast period of 2022-2027. More so, it is attributed to how mostly all vaccines in development uses genetic engineering and how the use of genetic engineering can help in creating products that can potentially target the disease without causing any ill-health effects.
Genome Editing/Genome Engineering Market Segmentation Analysis- By End User
The genome editing/ genome engineering market based on the end-users can be further segmented into Biotechnology and Pharmaceutical Companies, Academia and Research Centers, Contract Research Organizations, and Others. Pharmaceutical and Biotechnology held a dominant market share in the year 2021. For example, major vaccine manufacturers developed vaccines in the year 2021 and in the proceeding year. Moreover, governmental agencies supported their growth. For example, Pfizer received 1.95 billion dollars to develop the mRNA vaccines. Additionally, AstraZeneca’s vaccine known as Covishield uses the viral vector known as adenovirus and spliced the same gene to transfer information pertaining to the SARS virus.
However, CROs or Contract research organization is estimated to be the fastest-growing, with a CAGR of 13.8% over the forecast period of 2022-2027. It is owing to the major benefits it offers over the traditional ways. For example, by outsourcing activities pertaining to research and development, the patent holder needs not to spend excessive time and costs in selecting the right set of individuals, and hence, saves multitudes of costs. Additionally, giants such as Incyte, used approximately $2.216 billion on R&D activities, and out of which the predominant share was by clinical research conducted on off-site service locations.
Genome Editing/Genome Engineering Market Segmentation Analysis- By Geography
The Genome Editing/ Genome Engineering Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America’s genome editing/ genome engineering held a dominant share of 38% as compared to the other regions in the year 2021. The region’s predominant position in local infrastructure pertaining to giant bio-pharma companies. The concept of monoclonal antibodies was fuelled by the US. More so, the majority of the drug manufacturers are now into creating regenerative medicines for diabetes afflicted patients. As for 2020, the prevalence of Diabetes in Canada was 10% (for diagnosed); moreover, 29% of the population is unaware that they have diabetes. Trends remain constant for the US as well.
However, Asia-Pacific is set to offer lucrative opportunities to marketers in the projected period of 2022-2027. It is owing to the development of various CROs in the region and the favorable outlook for the government to allow FDI. AI and IoT have also started gaining prominence, which will allow the market to grow at a commendable pace.
Genome Editing/Genome Engineering Market Drivers
The role of AI has readily supplemented the growth of genetic engineering and has aided as a key market driver
Mistakes have no place when it comes to the use of genetic engineering, as a slight mishap can cause a major issue post-roll-out. Hence, machine learning and AI have been readily used in places where human labor was used. Moreover, a vast amount of data is present in one’s DNA, which goes beyond comprehension for a human being, hence, AI can help in gaining analysis. Additionally, the results obtained are gained through efficient methodologies and are at the same time more accurate. AI has been combined with 3D imaging to get clearer images. For example, technology can identify the presence of a glioma using brain scans of a patient with a very high rate of accuracy (over 97%). Neural networks and deep learning can identify the mutations, if any, and aid the doctor in performing surgeries in an enhanced manner. Moreover, there is no need to collect tissue using a biopsy.
The rising inclination of using regenerative medicines to counter the rising cases of complex diseases has aided the growth of the market
Stem cells have been gaining traction owing to their use to treat rare and common diseases. For example, regenerative medicines are actively used to treat the cases of diabetes. As per WHO, the prevalence of diabetes has grown 5x in the last four decades. Additionally, they predict the rate to go up as the sedentary lifestyle has emerged the pattern of global obesity, which is a prime reason for developing diabetes. Additionally, owing to the trend released by the CDC, the prevalence of diabetes in younger adults are growing in the last three years. A 4.2% YoY increase in type 2 diabetes has been notified in the US below age 20. Hence, beta cell replacement approaches have been used to treat patients afflicted with insulin resistance. For example, in CRISPR therapeutics, ViaCyte has pioneered the approach of generating pancreatic-lineage cells from stem cells and delivering them safely and efficiently to patients. Moreover, the company’s gene-editing technology protects the transplanted cells from the patient’s immune cells.
Genome Editing/Genome Engineering Market Challenges
The technological and ethical concerns surrounding the use of genome editing have hampered the growth of market and acted as a challenge for the market
Consumers are growing aware of the ingredients, moreover, two-third of the consumer decisions are now based on what is present on the item’s label. For example, GMO practices or Genetically Modified Organisms are highly intolerable in current scenarios, moreover, the brands are using tags such as “NON-GMO” and “obtained via sustainable practices” to lure consumers into their segment. But, however, gene editing in crops and plants helps to elongate the life of plants and improve the yield per hectare. Genome modifications, such as site-specific insertion, deletion, substitution, and epiallelic changes of the DNA in a cell or organism are all part of genome engineering, and there have been cases reported which suggests that their usage worsens the health conditions and are only favorable to the growers/manufacturers and not the end consumers. Lastly, the technology is used is not 100% reliant, and a cut at the wrong spot can cause troubles within. Hence, assessing the safety for gene therapies is a critical step that elongates the product cost/labor costs and also increases the technical know-how requirements.
Genome Editing/Genome Engineering Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Genome Editing/ Genome Engineering market. The top 10- Genome Editing/ Genome Engineering market companies are-
- Merck KGaA
- Recombinetics, Inc.
- Editas Medicine
- Precision Biosciences
- CRISPR Therapeutics
- Intellia Therapeutics, Inc.
- Cellectis S.A.
- In September 2021, mini-CRISP was developed. The bio-engineers have re-purposed the non-working CRISPR systems in order to make a smaller version of the genome engineering tool. More so, it is now easy to deliver the said into human cells, tissues, and other parts of the body. CasMINI's ability to delete and edit genes in lab-based human cells, including genes related to HIV infection, anti-tumor immune response, and anemia. It worked on almost every gene they tested, with robust responses in several.
- In April 2021, the grant from the Defence Advanced Research Projects Agency allowed the developers to find a different source of gene editor. Moreover, scientists have referred to it as “epigenetic”. It does not alter DNA sequences but changes how it is read in the cells. The gene silencing works with methylation, and the researchers used the switch or on-off switch to edit the gene.
- In January 2021, Researchers from the University of Pennsylvania used the CAS-9-CRISPR to knock out a potential protein, which is known as the stifle T-Cell. Additionally, the invention allows for the enhanced engineered cells to eliminate blood cancers in pre-clinical studies. Lastly, the researchers are optimistic, that with the use of such technology they will be able to reduce the severity of cancer by huge margins.
Genetic Testing Market- Forecast (2022-2027)
Report Code- HCR 0084
Gene Therapy Market- Forecast (2022-2027)
Report Code- HCR 0215
For more Lifesciences and Healthcare Market reports, please click here